Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

July 31, 2018

Study Completion Date

October 31, 2020

Conditions
Alpha-1 Antitrypsin DeficiencyEmphysemaChronic Obstructive Pulmonary Disease
Interventions
DRUG

Aspirin

81mg aspirin taken once per day in the morning

DRUG

Placebo

placebo taken once per day in the morning

OTHER

Withdrawal from alpha1 antitrypsin replacement therapy

After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.

Trial Locations (1)

10032

Columbia University, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Alpha-1 Foundation

OTHER

collaborator

Stony Wold-Herbert Fund, Inc.

OTHER

lead

Columbia University

OTHER